{
    "id": 23671,
    "fullName": "NRAS T58I",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "NRAS T58I lies within the GTP binding pocket of the Nras protein (UniProt.org). T58I has not been characterized, but can be predicted to confer a loss of function on Nras protein based on the effects of KRAS T58I, which results in defective intrinsic GTPase activity and decreased response to GTPase-activating proteins, leading to increased phosphorylation of of Mek and Akt, and transformation in cell culture (PMID: 16474405).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 840,
                    "pubMedId": 16474405,
                    "title": "Germline KRAS mutations cause Noonan syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474405"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "T58I",
    "createDate": "06/24/2016",
    "updateDate": "09/19/2018",
    "referenceTranscriptCoordinates": {
        "id": 162470,
        "transcript": "NM_002524",
        "gDna": "chr1:g.114713917G>A",
        "cDna": "c.173C>T",
        "protein": "p.T58I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24385,
                "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24384,
            "profileName": "NRAS T58I",
            "profileTreatmentApproaches": [
                {
                    "id": 16546,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "NRAS T58I"
                },
                {
                    "id": 16542,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NRAS T58I"
                },
                {
                    "id": 16543,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NRAS T58I"
                },
                {
                    "id": 16541,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NRAS T58I"
                },
                {
                    "id": 16545,
                    "name": "PIK3CA inhibitor",
                    "profileName": "NRAS T58I"
                },
                {
                    "id": 16544,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "NRAS T58I"
                }
            ]
        },
        {
            "id": 24385,
            "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162470,
            "transcript": "NM_002524",
            "gDna": "chr1:g.114713917G>A",
            "cDna": "c.173C>T",
            "protein": "p.T58I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}